Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, engages in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products in the People’s Republic of China. The company develops products in the areas of vascular interventional therapy for the treatment of atrial fibrillation, hypertension, and other cardiovascular diseases; and natural orifice transluminal endoscopic surgery for the treatment of urinary, respiratory, and digestive diseases. Its products include the Bladder Cryoablation System, a cryotherapy device for the treatment of non-muscle-invasive bladder cancer; the Gastric Cryoablation System, a self-developed cryoablation system indicated for performing cryoablation on gastric tumors to treat gastric cancer; the Esophageal Cryospray System, for intermediate to advanced esophagus cancer; the pulmonary nodule localization needle for CT-guided localization of lung nodules; the endoscopic clip for anastomosis for the closure of soft tissue in the digestive tract; the laparoscopic single-port multichannel access platform for laparoscopic surgery; the Atrial Fibrillation Pulsed Field Ablation System, for paroxysmal atrial fibrillation; the Anti-Gastroesophageal Reflux System, for gastroesophageal reflux disease; and other non-cryotherapy products. It also provides wound retractors for small incision surgery and minimally invasive surgery; ureteral dilation balloon catheters for ureteral stricture; laparoscopic biopsy bags for biopsy; and laparoscopic surgical instruments for laparoscopy applications. Cryofocus Medtech (Shanghai) Co., Ltd. was incorporated in 2013 and is based in Shanghai, the People’s Republic of China.
Metrics to compare | 6922 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6922PeersSector | |
---|---|---|---|---|
P/E Ratio | −15.8x | −17.4x | −0.5x | |
PEG Ratio | −0.58 | 0.02 | 0.00 | |
Price/Book | 20.9x | 2.4x | 2.6x | |
Price / LTM Sales | 14.1x | 6.7x | 3.3x | |
Upside (Analyst Target) | - | −4.2% | 43.3% | |
Fair Value Upside | Unlock | 3.6% | 6.9% | Unlock |